104 related articles for article (PubMed ID: 9394240)
1. [The in vitro antifungal activities of fluconazole against pathogenic yeasts recently isolated from clinical specimens].
Yamaguchi H; Igari J; Kume H; Abe M; Oguri T; Kanno H; Kawakami S; Okuzumi K; Fukayama M; Ito A; Kawata K; Uchida K
Jpn J Antibiot; 1997 Sep; 50(9):799-805. PubMed ID: 9394240
[TBL] [Abstract][Full Text] [Related]
2. [In vitro susceptibility to fluconazole of fungal strains freshly isolated from child patients with deep-seated mycoses].
Yamaguchi H; Uchida K
Jpn J Antibiot; 1993 Aug; 46(8):647-53. PubMed ID: 8230734
[TBL] [Abstract][Full Text] [Related]
3. [In vitro activity of a new semisynthetic echinocandin, micafungin, against clinical isolates of Candida species isolated in Tenri Hospital].
Komatsu M; Aihara M; Shimakawa K; Iwasaki M; Nagasaka Y; Fukuda S; Abe N; Matsuo S
Jpn J Antibiot; 2003 Dec; 56(6):705-11. PubMed ID: 15007879
[TBL] [Abstract][Full Text] [Related]
4. Antifungal drug resistance in pathogenic fungi.
Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibility of yeasts for fluconazole and itraconazole. Evaluation of a microdilution test.
Nenoff P; Oswald U; Haustein UF
Mycoses; 1999; 42(11-12):629-39. PubMed ID: 10680439
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of the isolation of Candida species from hospitalized patients.
Magalhães YC; Bomfim MR; Melônio LC; Ribeiro PC; Cosme LM; Rhoden CR; Marques SG
Braz J Microbiol; 2015 Mar; 46(1):117-23. PubMed ID: 26221096
[TBL] [Abstract][Full Text] [Related]
7. [In vitro antifungal activity of itraconazole, a new triazole antifungal agent, against clinical isolates from patients with systemic mycoses].
Uchida K; Matsuzaka A; Aoki K; Yamaguchi H
Jpn J Antibiot; 1991 May; 44(5):562-70. PubMed ID: 1652654
[TBL] [Abstract][Full Text] [Related]
8. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
9. In-vitro activity of dicationic aromatic compounds and fluconazole against Cryptococcus neoformans and Candida spp.
Del Poeta M; Bixel AS; Barchiesi F; Tidwell RR; Boykin D; Scalise G; Perfect JR
J Antimicrob Chemother; 1999 Aug; 44(2):223-8. PubMed ID: 10473229
[TBL] [Abstract][Full Text] [Related]
10. Role of yeasts as nosocomial pathogens & their susceptibility to fluconazole & amphotericin B.
Prasad KN; Agarwal J; Dixit AK; Tiwari DP; Dhole TN; Ayyagari A
Indian J Med Res; 1999 Jul; 110():11-7. PubMed ID: 10709333
[TBL] [Abstract][Full Text] [Related]
11. Fluconazole vs amphotericin B: "in vitro" comparative evaluation of the minimal inhibitory concentration (MIC) against yeasts isolated from AIDS patients.
Lombardi G; Gramegna G; Cavanna C; Michelone G
Microbiologica; 1990 Jul; 13(3):201-6. PubMed ID: 2273982
[TBL] [Abstract][Full Text] [Related]
12. [Species distribution and antifungal susceptibilities of yeast clinical isolates from three hospitals in Korea, 2001 to 2007].
Lee MK; Yong D; Kim M; Kim MN; Lee K
Korean J Lab Med; 2010 Aug; 30(4):364-72. PubMed ID: 20805708
[TBL] [Abstract][Full Text] [Related]
13. Effect of culture media on in vitro susceptibility testing of fluconazole against some yeasts.
Sekhon AS; Garg AK; Hamir Z
Mycoses; 1991; 34(7-8):319-22. PubMed ID: 1803235
[TBL] [Abstract][Full Text] [Related]
14. [In vitro pharmacological study of fluconazole. Evaluation of an antifungal assay].
Duval F; Lavarde V
Pathol Biol (Paris); 1993 May; 41(5):469-73. PubMed ID: 8414680
[TBL] [Abstract][Full Text] [Related]
15. In vitro antifungal activity of a novel lipopeptide antifungal agent, FK463, against various fungal pathogens.
Uchida K; Nishiyama Y; Yokota N; Yamaguchi H
J Antibiot (Tokyo); 2000 Oct; 53(10):1175-81. PubMed ID: 11132964
[TBL] [Abstract][Full Text] [Related]
16. [Onychomycosis-causing yeasts in four Mexican dermatology centers and their antifungal susceptibility to azolic compounds].
Manzano-Gayosso P; Méndez-Tovar LJ; Arenas R; Hernández-Hernández F; Millán-Chiu B; Torres-Rodríguez JM; Cortés-González E; Fernández R; López-Martínez R
Rev Iberoam Micol; 2011; 28(1):32-5. PubMed ID: 21147249
[TBL] [Abstract][Full Text] [Related]
17. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
Fujita S
Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
[TBL] [Abstract][Full Text] [Related]
18. Azole resistance in neonatal intensive care units in Argentina.
Giusiano G; Mangiaterra M; Rojas F; Gómez V
J Chemother; 2005 Jun; 17(3):347-50. PubMed ID: 16038532
[TBL] [Abstract][Full Text] [Related]
19. [Yeast infections: causative agents and their antifungal resistance in hospitalized pediatric patients and HIV-positive adults].
Rodero L; Boutureira M; Demkura H; Burkett A; Fernández C; Losso M; Jáuregui Rueda H; Monticelli A; Vitale R; Canteros C; Hochenfellner F; Vivot W; Davel G
Rev Argent Microbiol; 1997; 29(1):7-15. PubMed ID: 9229726
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo antifungal activities of the eight steroid saponins from Tribulus terrestris L. with potent activity against fluconazole-resistant fungal pathogens.
Zhang JD; Cao YB; Xu Z; Sun HH; An MM; Yan L; Chen HS; Gao PH; Wang Y; Jia XM; Jiang YY
Biol Pharm Bull; 2005 Dec; 28(12):2211-5. PubMed ID: 16327151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
